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Abstract
Purpose: This study is a dosimetric and acute toxicity comparison of endometrial cancer
patients treated with either Axxent (Xoft, Inc., San José, CA, USA) electronic and interstitial
brachytherapy versus interstitial high dose rate brachytherapy (HDRBT). Materials and
Methods: Between 2015 and 2017, 94 patients with postoperative endometrial cancer were
treated in our centre with the Axxent electronic brachytherapy (eBT) system. The V150 and
V200 are evaluated prospectively for each plan. The mean age of patients was 65.9 years (age
range 33–84 years), with different tumour staging. Of the 94 patients, 37 received exclusive
adjuvant brachytherapy (25Gy in five sessions); the remaining patients received external
beam radiotherapy (EBRT) with a regimen of 23 sessions of 2Gy each to the entire pelvis,
followed by eBT (15Gy in three sessions). Additionally, the absorbed doses received by the
organs at risk (OAR), urinary bladder, rectum and sigmoid colon were compared with
HDRBT plans, evaluating D2cc, V50% and V35%. Median follow-up was done for each of the 94
patients to assess the toxicity of the treatment: vaginal mucosa toxicity, rectal and urinary
toxicity; and results are presented for acute toxicity, toxicity at 1 month after the end of
treatment and follow-up after 12 months for a portion of patients according to the Radiation
Therapy Oncology Group (RTOG) toxicity criteria. Results: The doses in OAR for eBT plans
were lower than that for HDRBT plans, both Ir-192 and Co-60 plans, whose doses were
similar. The dose in bladder with eBT was 63.8% of the prescribed dose for D2cc versus 70.1%
for HDRBT Ir-192, for V50% was 7.2% versus 12.7% and for V35% was 15.2% versus 28.2%. In
rectum the D2cc was 61.2% versus 68.4%, for V50% was 7.9% versus 14.3% and for V35% was
16.7% versus 32%. Results demonstrated lower doses to OAR in all eBT plans. Acute toxicity
in eBT was very low in cases of mucositis, with only one case of toxicity greater than grade 1,
rectal toxicity and urinary toxicity; results at 1 month are equally good, toxicity symptoms
disappeared and no relapses have occurred to date. Conclusions: The results of treatment with
the Axxent eBT unit for 94 patients are very good, as no recurrence has been observed and the
toxicity of the treatment is very low. The increase in V150 and V200 has not produced an
increase in vaginal mucosa toxicity, and the doses in the OAR are lower than in the plans
implemented for HDRBT with Ir-192 or Co-60. eBT is a good alternative to treat endometrial
cancer in centres without conventional HDR availability. To date, there are limited published
studies reporting on outcomes from patients treated with eBT.
Purpose
Electronic brachytherapy (eBT) has been evolving since the turn of the century1 and has
become a treatment option for different types of tumour locations in various scenarios.2–6 The
Axxent eBT unit (Xoft, Inc., an iCAD subsidiary, San José, CA, USA) provides treatment to
patients with a 50 kVp miniature X-ray source that directly irradiates the tumour site in skin
cancer and with different applicators in the case of breast or gynaecological cancers. This unit
allows treatment of skin tumour lesions (nonmelanoma), performance of intraoperative breast
radiotherapy and postoperative endometrial and cervical cancer treatments. Specifically, it can
also be used to treat local and locally advanced endometrial cancer in protocols that require
high absorbed dose rate (HDR) after a hysterectomy and/or external radiotherapy.7 At our
centre, the eBT system was acquired in May 2015 to be used in skin locations and in
intraoperative radiotherapy procedures for breast cancer after lumpectomy. From September
2015, postoperative endometrial cancer treatments began and were carried out with Axxent
eBT unit. Traditionally, this type of treatment has been carried out in many centres
throughout the world with HDR equipment with Iridium-192 (Ir-192, 73.8-day half-life and
average energy of 0.355MeV) sources that irradiate the vaginal vault by a cylindrical
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applicator of an appropriate size for each case (generally, the
largest size possible, given the patient’s anatomy).8 Other sources
have been used for this purpose, such as Cobalt-60 (Co-60, 5.27-
year half-life and average energy of 1.25MeV),8 with the advan-
tage that there are fewer source changes; therefore, it is more
economical, although each brachytherapy session is longer.
Previous published studies for patients treated with Ir-192
compared endometrium,9,10 cervix11 and breast,12 and always
showed a lower dose in the organs at risk (OAR) for patients
planned with eBT. In all these studies patients were treated with
Ir-192, but in our work patients are treated with eBT and we
report the monitoring of early toxicity as one of the main
objectives of this research.
The aim of this study was to undertake a dosimetric com-
parison of traditional HDR brachytherapy and eBT to ensure the
safety and results in terms of toxicity in OAR. The objective of
treatment with eBT is to provide an alternative to the afore-
mentioned radioactive sources with a portable unit, with the
resulting advantage of mobility, absence of room shielding (for
this energy, an 0.5mm Pb-equivalent shield in walls and doors is
sufficient), avoiding the need to transport and change radio-
isotope sources and their ease of use.13
Materials and Methods
A total of 94 patients were treated with the Axxent eBT unit from
September 2015 to October 2017 using cylindrical applicators of
sizes ranging from 2.5 to 3.5 cm in diameter, with active lengths
of 2.5 to 3.5 cm (Table 1). Each eBT source has a working life of
500min of clinical use, discounting the quality assurance time;
each endometrium session lasted between 3 and 4min. If a source
is not stable or when 500min of treatment have been reached, it is
removed and replaced (Table 2). Ethical approval was gained
from Research Ethics Committee of the Autonomous Commu-
nity of Aragon for the study. The mean age of patients was 65.9
years (33–84 years), with different tumour staging (Table 3). All
patients presented with endometrial cancer during this time-
frame. Of the 94 patients, 37 received exclusive adjuvant eBT
[stage IA cases according to Fédération Internationale de Gyné-
cologie et d’Obstétrique (FIGO) and seven patients with IB1
FIGO stage] (25Gy in five sessions); the remaining patients
received adjuvant external beam radiotherapy (EBRT) with a
regimen of 23 sessions of 2Gy each to the entire pelvis, followed
by eBT (15Gy in three sessions). Sessions were administered
twice weekly (Monday and Friday) after EBRT treatment ends.
In patients treated with EBRT and eBT, the time from EBRT and
the end of eBT is 58.1 days (35–78 days), and the time between
the end of radiotherapy and the end of eBT is 14.7 days (6–
35 days) (Table 3). Before radiotherapy, 33 patients (35%)
received chemotherapy treatment and 61 did not (65%). Cal-
culations made for the patients are compared with the calcula-
tions made a posteriori for Ir-192 and Co-60 sources for each of
the 94 patients, giving a total of 282 different plans. For eBT,
each patient underwent a computed tomography study with
sections every 3mm before the first session. The different OARs
of interest were contoured; in this case, the urinary bladder,
rectum and sigmoid colon, following the recommendations of
the American Brachytherapy Society.14 Then the planning target
Table 1. Cylinder size and active lengths
d (cm) Active length (cm) n %
2.5 2.5 3 3
2.5 3 10 11
2.5 3.5 1 1
3 2.5 5 5
3 3 30 32
3 3.5 3 3
3.5 2.5 3 3
3.5 3 37 39
3.5 3.5 2 2
Abbreviations: d: cylinder diameter; n: number of patients.
Table 2. Characteristics of electronic brachytherapy sources
Working life of eBT sources
500min of clinical
use
Deviation allowed with respect to calibration
certificate
< 10%
Deviation allowed with respect to first measure < 5%
Maximum energy 50 kVp
Average energy 29.6 keV
Table 3. Patient and treatment characteristics
Patients 94













EBRT + eBT 57 patients
Time EBRT to eBT OTT
14·7 (6–35) days 58·1 (35–78) days
eBT exclusive 37 patients
Notes: Proportions are given with number of total and median range. FIGO stage is given in
percentage of the total number of patients.
Abbreviations: eBT, electronic brachytherapy treatment; Time EBRT to BQ, time between the
end EBRT and the start of eBT; OTT, overall treatment time; Total time: time from the start
of the EBRT to the end of the eBT.
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volume (PTV) was contoured and defined by the cylinder along
its active length plus a 5mm margin with the cylinder volume
removed from the PTV. The objective is to provide the pre-
scribed dose at 5mm from the applicator throughout its active
length.14 After the medical physicist prepared the plan, the
radiation oncologist approved it, and if appropriate, the patient
was treated. Subsequently, two more plans were produced for
treatment with Ir-192 and Co-60 sources, respectively.15–18 The
units that we defined in the treatment planning system (TPS) for
this purpose are Gammamed Plus (Varian Medical System, Inc.)
for the Ir-192 and Eckert & Ziegler Bebig for calculations with
Co-60. TG-43 is the algorithm available in our TPS, with which
we perform all calculations. In data referring to the PTV, the
values of the dose at 90% of the PTV (D90) and of the volume
that receives 100% of the dose (V100) have been determined, but
will not be shown in this research, as they are the same in the
three treatment plans produced, and the same standardisation is
implemented in all planning. The V150 and V200 were also
determined. With regard to the OAR, we determined the same
parameters for all OAR of interest in the study: urinary bladder,
rectum and sigmoid colon. The parameters compared are D2cc
(maximum dose at 2 cc of volume), V50% (volume up to 50% of
the prescribed dose) and V35% (volume up to 35% of the pre-
scribed dose) and assessed toxicity according to the Radiation
Therapy Oncology Group (RTOG) parameters.19
Results
The mean follow-up of patients was 14 months (4–25). The
dosimetry results obtained for patients planned with eBT show
much lower doses in OAR than those planned with Ir-192. The
mean dose parameters of all treatments compared showed that
the bladder D2cc for eBT was 63.8% versus 70.1% for HDRBT
Ir-192 with the difference in the V50% (7.2% versus 12.7%) and
V35% (15.2% versus 28.2%) being much more remarkable.
Also, in the rectum we observed 61.2% versus 68.4% in D2cc,
7.9% versus 14.3% in V50% and 16.7% versus 32% in V35%. The
results for HDRBT Co-60 were similar to those obtained for Ir-
192 (Table 4).
The D90 of each plan was not included in the results, as it was
the value used to standardize each plan. The V150 and the V200
were higher for cases calculated (and treated) with Axxent than
for those calculated with Ir-192 or Co-60, although this differ-
ence decreases as the cylinder size increases (Table 5). Acute
mucositis cases in patients have not been observed: of the 94
patients treated in our centre, only one presented grade 2
(RTOG) acute toxicity (Table 6).19 One month after treatment,
the patients’ vaginal toxicity was grade 0 (RTOG) for 94.7% of
the patients and grade 1 for the remaining 5.3%, with grade 2
cases completely disappearing. Rectal toxicity grade 0 was 98.9%
and grade 1 was 1.1%, and urinary toxicity grade 0 was 97.9%
and grade 1 was 2.1% (Table 7). We observed that patients for
whom 12 months have already passed since treatment ended,
that is 31 patients, and median follow-up of 19 months (12–
25 months) did not present any recurrence. The prescribed dose
in each eBT treatment was implemented without considering
that we administered treatment with a much lower average beam
energy than in the case of Ir-192 (26 keV compared with
355 keV) and therefore, without considering the differences in
the different relative radiobiological effectiveness (RBE) expec-
ted for low-energy irradiation.20–22
Discussion
Results were obtained in patients treated after the first 25 months,
with median follow-up of 14 months (4–25 months), on the clinical
Table 4. Mean values of dosimetric parameters
PTV
%(PTV vol.)
n= 94 Axxent 50 kV SD Ir-192 SD Co-60 SD
V150% 20.1 6.0 8.6 4.9 7.7 4.5
V200% 1.4 1.5 0.1 0.2 0.1 0.2
Bladder
D2cc (%PD) 63.8 17.6 70.1 14.3 68.8 14.1
V50% (%vol.) 7.2 6.6 12.7 9.9 12.0 10.8
V35% (%vol.) 15.2 12.1 28.2 18.7 26.1 17.2
Rectum
D2cc (%PD) 61.2 18.3 68.4 16.2 66.9 15.5
V50% (%vol.) 7.9 6.4 14.3 10.8 12.8 10.1
V35% (%vol.) 16.7 11.8 32.0 19.3 29.4 18.1
Sigmoid colon
D2cc (%PD) 48.2 21.3 57.8 18.2 56.2 18.4
V50% (%vol.) 8.6 10.8 16.2 15.9 15.8 17.0
V35% (%vol.) 21.1 20.6 37.4 23.5 34.9 23.7
Abbreviations: PTV, planning target volume; V150 and V200, percentage of the PTV receiving 150%
and 200% of the prescribed dose; D2cc, maximum dose of 2 cc; %PD, percentage of the pre-
scribed dose; V50% and V35%, percentage of organ receiving 50% or 35% of the prescribed dose.
Table 5. Mean values per cylinder size
%PTV vol. %PTV vol.
n= 14














Abbreviations: n, number of patients; d, cylinder diameter; V150 and V200: percentage of the
PTV receiving 150% and 200% of the prescribed dose.
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use of the Axxent eBT unit for postoperative treatment of endo-
metrial cancer, indicating why this option is a good alternative.
It is possible to obtain the same vaginal vault coverage as in the
planning when using Ir-192 or Co-60, and reduction of doses to
OAR is achieved although the V150 and the V200 of the PTV is
increased, which could have produced an increase in acute
mucositis cases in our patients but the results of toxicity, together
with the dose reduction to OAR, lead us to conclude that eBT is a
good alternative to treatments with Ir-192 or Co-60. In another
study of only 10 patients treated with Ir-192 and Co-60 and
comparing the treatment plans with eBT (10) results reported a
difference in rectum for D2cc between eBT and Ir-192 (86.7%
versus 88.3% of prescribed dose) but similar results for V35%
(36.9% versus 58.9%) and V50% (20.4 versus 32.7); for the bladder
the D2cc was 43.3% for eBT and 55% of the dosage prescribed for
Ir-192 with V35% (37.9 versus 72.3) and V50% (15.6 versus 33.9).
In a multicentre study of patients treated with eBT,23 the results
are similar to this study: dose to the bladder at V50% of
11.5± 9.7% and rectum 17.4±10.9% in eBT plans.
Considering these results, the authors believe that eBT is a
good option for a radiation oncology department without a bra-
chytherapy unit (since additional research is needed with longer
follow-up) for the treatment of endometrial cancer, given the
mobility, versatility and ease of installation of the equipment
combined with appropriate dosimetry results and very low toxi-
city in patients, according to the initial results shown. In the
absence of a longer clinical follow-up, the results are highly
promising. With regard to the calculation method used, it is
recommended24 to consider the composition of the tissues and
perform calculations based on Monte-Carlo models. Our calcu-
lations are performed with TG-43 without correction for het-
erogeneity because it is the algorithm available in our centre and
in many other hospitals for which these results will be useful.
Although Monte-Carlo methods have been compared with the
clinical results of other radionuclides, Reniers et al. came to the
conclusion that eBT source has similar RBE as the 125I isotope,20
for Axxent eBT, the published RBE values are still pending
clinical verification.25 Studies have been done to determine the
RBE of 50 keV eBT sources used in this type of treatment, where
RBE factors are calculated for different tissues. RBE calculated by
Brenner et al. varies between 1.29 and 1.85 with respect to the Ir-
192 to 5mm depth.21 Publications, after carefully reviewing the
prescription of treatments according to these factors,21,25,26 always
recommend that this be done with caution and based on clinical
studies; following these recommendations, we should have
reduced the prescribed dose to prevent toxicities, and we may
have reduced local control. A clinical study showed the reduction
of the prescribed dose in the treatment of nodular and superficial
basal cell carcinoma, using eBT, based on RBE decreased tumour
control from 95 to 90%, showing more tumour control for
standard prescription.27 In reference to the postoperative endo-
metrial cancer treatment, Rava et al. showed a dose decrease in
the urinary bladder and rectum, taking into account the equiva-
lent biological dose for an α/β= 3 (BED3) with eBT, which may
be related to a decrease of late toxicity in these organs; all of this
was calculated with an RBE factor of 1.5. However, in the same
study, there was a dose increase on the surface of the mucosa if we
calculate for this same RBE the equivalent doses BED10 and
BED3, which would give an overdose to the vaginal vault and
higher toxicity of the mucose. Rava et al. suggest considering de-
escalation of the dose to account for the differences in RBE,26
again recommending more clinical studies to consider. Therefore,
more studies must be conducted, and more improvements must
be made in dosimetry calculation with eBT to compensate for the
difference in RBE, although there are important uncertainties in
the estimation of this parameter, which imply that the results may
vary from one publication to another; it is a subject for discus-
sion.28 In our case, not using corrections of the RBE has not
caused an increase of mucositis or any other toxicity or inade-
quate local control (only 30 patients had a 12 months follow-up).
This study represents the largest published series of patients with
endometrial cancer treated with eBT to date, showing excellent
results in terms of early effects in all patients with a much lower
dose in OAR than in patients treated with sources of Ir-192 or
Co-60. Higher values of V150 and V200 in the case of eBT do not
result in higher cases of toxicity to the vaginal mucosa. The dose
differences in the OARs are very marked, especially in the V35%
and V50% are analysed.
Conclusion
The eBT treatments are a great advantage in centres without HDR
equipment, although more clinical and local control results with
longer follow-up are needed. The eBT equipment is a useful
addition to centres with HDR equipment, as a complimentary
facility due to its mobility and versatility in being able to perform
treatments for endometrial cancer, intraoperative breast radio-
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